Anyway, It seems EXEL has slowed down HCC enrollment since last Octorber. Don't know it's due to tight budget or human resource.
NCT01954745 is about to finish. It's one indication that cabo may fit in for EGFR and c-Met mutations.I am wondering if it's economically viable to run a phase III trial for 2nd/3rd line for a rare cancer, since if phase II is good doctors will have to prescribe it without other better choices. MTC was another story because it was kinda like verification of concepts. Or we should be going after bigger indications first?
It's an open label trial with research in mind. So I guess the interim analysis are running everyday implicitly.
Japanese trial enrollment is so quick. A phase II trial of CS-3150 needs to recruit 400 patients, started on January19, and finished enrollment at May7, expecting Primary Completion Date to be December. Why seriously did it take so long to start?
They had all their forms ready before the cut-off date. Only to fill the blanks after the data. That's why it took them less than 20 days to submit NDA after PR. What was MMM doing? Trimming hair.
75 slots（=7500 shrs) or 75 shares? If only 75 shares, congratulations! You made a killing with $200 and something. It's extremely hard considering transaction fee.
Who has all the NK, CAR-T, Check point, targeted chemical candidates? And how much does it cost for you to buy them all? 1/15! comparing to FBIO, NK is expensive.
2015_05_27's change, you can see how many deletions are there. Don't forget to uncheck "Hide non-essential portions"
It's like an XML files compare.
If you check the update status of celestial, you may find something interesting. After 2014_10_27, they suddenly stopped updating for half year. That was normal behavior like before then. And then finally came out saying that clinical trial sites amount was cut. It sounds like they slow down enrollment after the big layoff.